• @[email protected]
    link
    fedilink
    3
    edit-2
    8 months ago

    I agree it may have presented barriers for coordination the FDA and access to US markets. I haven’t been able to dig deep into the Cuban studies, but just because something is labeled a phase 3 or phase 4 by the investigators doesn’t necessarily mean it was done to the standards necessary for fda approval or in the correct context of current standard of care treatments in the US or who knows how many other issues. If it was fully ready for all markets as is and required no further investigations, and it was only the US FDA causing problems, I would expect it to have already been widely available in many other countries that don’t have embargos with Cuba, like all of Europe. Currently it’s only available in Cuba, Colombia, Bosnia and Herzegovina, Peru, and Paraguay.

    Mostly though I didn’t want someone to accidentally misread this and think it meant cure. I realize you did not say that, but it’s just a common misreading I’ve noticed people make of the term cancer vaccines when they’ve been mentioned in popular media. Didn’t want someone to drag their poor dying relative off to Paraguay thinking they’re getting cured.

    I agree the Cuban embargo is ridiculous, should be stopped, and is hurting both countries with no benefit to anyone (other than keeping a certain segment of voters in Florida happy).

    • @[email protected]
      link
      fedilink
      28 months ago

      like all of Europe

      While Europe does not have an embargo, up until 2016 the EU and Cuba basically had 0 relationship. The EU created “The Common Position” in 1996 which was “to encourage a process of transition to a pluralist democracy” in Cuba which the Cuba government rejected as meddling in their internal affairs.

      Then in the 2000s there was a bigger spat where Cuba even started rejecting EU aid.

      But since 2017 they’ve actually really warmed relations so this is a super good point!

      Thank you for kicking off these research dives with your comments.